Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Durable efficacy of lenzilumab plus azacitidine in newly diagnosed proliferative CMML patients: Interim analysis after four years of study commencement

Devendra Hiwase, David Ross, David Yeung, Agnes Yong, Steven Lane, Anna Brown, Chun Yew Fong, Timothy Hughes, John Reynolds, Daniel Thomas

Blood (2025) 146 (Supplement 1): 3855.

https://doi.org/10.1182/blood-2025-3855

Published: 2025

Journal Articles

Trial in progress: A Phase IIb randomized clinical trial combining oral azacitidine and vididencel, a novel immunotherapy, for post-remission / maintenance therapy for adult patients with cytogenetically intermediate and high-risk Acute Myeloid Leukemia (ALLG AMLM22/D4 CADENCE)

Victoria Ling, Paula Marlton, John Reynolds, Mark Dawson, Robin Gasiorowski, Hannah Rose, Chun Yew Fong, Jake Shortt, Anoop Enjeti, Carolyn Grove, Joanna Nkyekyer, Nadia Munsef, Andrew Wei

Blood (2025) 146 (Supplement 1): 5210.

https://doi.org/10.1182/blood-2025-5210

Published: 2025

Journal Articles

Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study (AMaRC 19-01; ALLG MM22)

Sueh-Li Lim, John Reynolds, Lucy Pemberton, Tricia Wright, Sophie Lee, Peter Mollee, Anita C. Shetty, Yu Jin Kim, Weston Helen, Byard Nina, Khoa Le, Zoe McQuilten, Hang Quach, Andrew Spencer

Blood (2025) 146 (Supplement 1): 5842.

https://doi.org/10.1182/blood-2025-5842

Published: 2025

Journal Articles

An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma (MM) incorporating iberdomide, isatuximab, and dexamethasone – the IBIS study amarc 20-01.

Sueh-Li Lim, Sridurga Mithraprabhu, John Reynolds, Wojciech Janowski, Noemi Horvath, Hang Quach, Philip Campbell, Georgia McCaughan, Yu Jin Kim, Thalia Peres Suarez, Sophie Lee, Phillip Wong, Byard Nina, Priyanka Meet, Khoa Le, Andrew Spencer

Blood (2025) 146 (Supplement 1): 5841.

https://doi.org/10.1182/blood-2025-5841

Published: 2025

Journal Articles

Unravelling the epigenetic drivers of chip – MDS/CMML – AML progression through novel methylation-sensitive regulatory elements

Yanjing Liu, Li Chai, Devendra Hiwase, David Ross, David Yeung, Agnes Yong, Steven Lane, Anna Brown, Chun Yew Fong, Timothy Hughes, John Reynolds, Daniel Thomas, Daniel Tenen, Mahmoud Bassal

Blood (2025) 146 (Supplement 1): 3231.

https://doi.org/10.1182/blood-2025-3231

Published: 2025

Journal Articles

MRD intervention in AML: A new therapeutic horizon

Andrew H Wei, Harry J Iland, Courtney D. DiNardo, John Reynolds

Blood blood.2025029010.

https://doi.org/10.1182/blood.2025029010

Published: 2025

Journal Articles

Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML

Rithin Nedumannil, Michael Ashby, James Rowland, Jacques A. J. Malherbe, Jared Fairbank, Kelli Gray, Sun Loo, Matthew Wright, John Reynolds, Devendra Hiwase, Paula Marlton, Shaun Fleming, Ashish Bajel, Andrew H. Wei

Blood (2025) 146 (13): 1625–1629.

https://doi.org/10.1182/blood.2025028594

Published: 2025

Includes: Supplemental data

Journal Articles

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study

Blood (2024) 144 (19): 1993–2001.

https://doi.org/10.1182/blood.2024024657

Published: 2024

Includes: Supplemental data

Journal Articles

Initial Results from the Frailty-Stratified, Randomised Controlled Bayesian Adaptive Trial of Bortezomib Versus Lenalidomide in Transplant Ineligible Myeloma (TI-NDMM) - the FRAIL-M Study (AMaRC 19-01; ALLG MM22)

Sueh-Li Lim, John Reynolds, Lucy Pemberton, Tricia Wright, Sophie Hyesuk Lee, Peter Mollee, Anita C Shetty, Helen Weston, Nina Byard, Khoa Le, Zoe K McQuilten, Hang Quach, Andrew Spencer

Blood (2024) 144 (Supplement 1): 4755.

https://doi.org/10.1182/blood-2024-209640

Published: 2024

Journal Articles

Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare

Blood (2024) 144 (Supplement 1): 476.

https://doi.org/10.1182/blood-2024-201218

Published: 2024

Journal Articles

Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A- rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial

Blood (2024) 144 (Supplement 1): 223.

https://doi.org/10.1182/blood-2024-202895

Published: 2024

Journal Articles

A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial

Blood (2024) 144 (Supplement 1): 217.

https://doi.org/10.1182/blood-2024-199882

Published: 2024

Journal Articles

Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine

Devendra Hiwase, David M Ross, David T Yeung, Agnes S. M. Yong, Steven W Lane, Anna Brown, Chun Yew Fong, Timothy P Hughes, John Reynolds, Daniel Thomas

Blood (2024) 144 (Supplement 1): 1006.

https://doi.org/10.1182/blood-2024-202867

Published: 2024

Journal Articles

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Blood (2023) 142 (23): 1960–1971.

https://doi.org/10.1182/blood.2023020301

Published: 2023

Includes: Supplemental data

Journal Articles

A Phase I/II Single Arm Study of Belantamab Mafodotin, Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Planned Interim Analysis of Safety and Efficacy. Amarc 19-02 Belacard Study

Masa Lasica, Andrew Spencer, Noemi Horvath, Wojt Janowski, Douglas Coghlan, Craig Wallington-Gates, Philip Campbell, Hock Choong Lai, Georgia McCaughan, Nicholas Weber, Anish Puliyayil, Philip Wong, Deng Yachao, Khoa Le, John Reynolds, Hang Quach

Blood (2023) 142 (Supplement 1): 2012.

https://doi.org/10.1182/blood-2023-189005

Published: 2023

Journal Articles

Evaluation of Easym, a Clonotypic Mass Spectrometry Assay, and Euroflow Minimal Residual Disease Assessment in Multiple Myeloma

Jessie Zhao, Tiffany T. Khong, Malgorzata Gorniak, Abir Khaled, Zac McDonald, John Reynolds, Daniel Wong, Nicholas Bingham, Anna M. Johnston, Olga Motorna, Nicholas E. Murphy, Hang Quach, Liqiang Yang, Andrew Spencer

Blood (2023) 142 (Supplement 1): 3328.

https://doi.org/10.1182/blood-2023-179742

Published: 2023

Journal Articles

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Primary Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Slavisa Ninkovic, Costas K. Yannakou, Nicholas Murphy, Rosemary Anne Harrup, Craig Wallington-Gates, Magdalena Sobieraj-Teague, M Hasib Sidiqi, Anish Puliyayil, Wojt Janowski, John Reynolds, Andrew Spencer, Hang Quach

Blood (2023) 142 (Supplement 1): 2019.

https://doi.org/10.1182/blood-2023-185944

Published: 2023

Journal Articles

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

Blood (2023) 142 (Supplement 1): 865.

https://doi.org/10.1182/blood-2023-172583

Published: 2023

Journal Articles

Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

Blood (2023) 142 (Supplement 1): 1295.

https://doi.org/10.1182/blood-2023-181541

Published: 2023

Journal Articles

Circulating RAS/RAF and DNA-Repair Gene Mutations Associates with High-Risk/Treatment Resistance in Primary Refractory Multiple Myeloma

Sridurga Mithraprabhu, John Reynolds, Rose Turner, Hang Quach, Noemi Horvath, Ian H Kerridge, Flora Yuen, Tiffany Khong, Brian G.M. Durie, Andrew Spencer

Blood (2022) 140 (Supplement 1): 9933–9934.

https://doi.org/10.1182/blood-2022-171053

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Durable efficacy of lenzilumab plus azacitidine in newly diagnosed proliferative CMML patients: Interim analysis after four years of study commencement

Trial in progress: A Phase IIb randomized clinical trial combining oral azacitidine and vididencel, a novel immunotherapy, for post-remission / maintenance therapy for adult patients with cytogenetically intermediate and high-risk Acute Myeloid Leukemia (ALLG AMLM22/D4 CADENCE)

Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study (AMaRC 19-01; ALLG MM22)

An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma (MM) incorporating iberdomide, isatuximab, and dexamethasone – the IBIS study amarc 20-01.

Unravelling the epigenetic drivers of chip – MDS/CMML – AML progression through novel methylation-sensitive regulatory elements

MRD intervention in AML: A new therapeutic horizon

Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study

Initial Results from the Frailty-Stratified, Randomised Controlled Bayesian Adaptive Trial of Bortezomib Versus Lenalidomide in Transplant Ineligible Myeloma (TI-NDMM) - the FRAIL-M Study (AMaRC 19-01; ALLG MM22)

Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare

Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A- rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial

A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial

Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

A Phase I/II Single Arm Study of Belantamab Mafodotin, Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Planned Interim Analysis of Safety and Efficacy. Amarc 19-02 Belacard Study

Evaluation of Easym, a Clonotypic Mass Spectrometry Assay, and Euroflow Minimal Residual Disease Assessment in Multiple Myeloma

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Primary Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

Circulating RAS/RAF and DNA-Repair Gene Mutations Associates with High-Risk/Treatment Resistance in Primary Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only